| Popis: |
To improve the diagnosis and treatment of chronic pain (CP), establishing reliable and objective biomarkers is a central challenge (Davis et al., 2020). Resting state electroencephalography (rsEEG) is a promising tool for biomarker development in CP. Recently, evidence was found for stronger oscillatory brain activity at theta (3-8 Hz) and beta (13-30 Hz) frequencies in patients compared to healthy participants (Zebhauser et al., 2023). EEG-based connectivity and network measures are other biomarkers candidates (Lee et al., 2021; Ploner and Tiemann, 2021). However, most patients with CP take centrally acting analgesics whose confounding effects on rsEEG-variables are largely unknown yet. In this study, we aim to evaluate effects of opioids, analgetic antiepileptics and analgetic antidepressants on a range of rsEEG-biomarker candidates for CP. Effects will be evaluated in two independent existing datasets of patients with CP. |
